These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 2586765

  • 1. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
    Rondot P, Ziegler M, Aymard N, Teinturier A.
    Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765
    [Abstract] [Full Text] [Related]

  • 2. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
    Goetz CG, Tanner CM, Gilley DW, Klawans HL.
    Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764
    [Abstract] [Full Text] [Related]

  • 3. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK, Rinne JO.
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [Abstract] [Full Text] [Related]

  • 4. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
    Deleu D, Jacques M, Michotte Y, Ebinger G.
    Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
    [Abstract] [Full Text] [Related]

  • 5. An open multicenter long-term treatment evaluation of Sinemet CR. Sinemet CR Multicenter Study Group.
    Bush DF, Liss CL, Morton A.
    Neurology; 1989 Nov; 39(11 Suppl 2):101-4; discussion 105. PubMed ID: 2685646
    [Abstract] [Full Text] [Related]

  • 6. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
    Hutton JT, Morris JL, Bush DF, Smith ME, Liss CL, Reines S.
    Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
    Yeh KC, August TF, Bush DF, Lasseter KC, Musson DG, Schwartz S, Smith ME, Titus DC.
    Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
    [Abstract] [Full Text] [Related]

  • 8. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations.
    Jankovic J, Schwartz K, Vander Linden C.
    Mov Disord; 1989 Nov; 4(4):303-9. PubMed ID: 2682215
    [Abstract] [Full Text] [Related]

  • 9. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
    Feldman RG, Mosbach PA, Kelly MR, Thomas CA, Saint Hilaire MH.
    Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
    [Abstract] [Full Text] [Related]

  • 10. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
    LeWitt PA, Nelson MV, Berchou RC, Galloway MP, Kesaree N, Kareti D, Schlick P.
    Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
    [Abstract] [Full Text] [Related]

  • 11. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [Abstract] [Full Text] [Related]

  • 12. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
    Mark MH, Sage JI.
    Ann Clin Lab Sci; 1989 Nov; 19(2):101-6. PubMed ID: 2665626
    [Abstract] [Full Text] [Related]

  • 13. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H.
    Neurology; 2005 Jan 25; 64(2):216-23. PubMed ID: 15668416
    [Abstract] [Full Text] [Related]

  • 14. Long-term clinical efficacy of Sinemet CR in patients with Parkinson's disease.
    Rodnitzky RL, Dickins QS, Dobson J.
    Neurology; 1989 Nov 25; 39(11 Suppl 2):92-5; discussion 95. PubMed ID: 2586769
    [Abstract] [Full Text] [Related]

  • 15. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
    Metman LV, Hoff J, Mouradian MM, Chase TN.
    Mov Disord; 1994 Jul 25; 9(4):463-5. PubMed ID: 7969216
    [Abstract] [Full Text] [Related]

  • 16. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
    Aarli JA, Gilhus NE.
    Neurology; 1989 Nov 25; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767
    [Abstract] [Full Text] [Related]

  • 17. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G, Liss C, Reines S, Irr J, Nibbelink D.
    Eur Neurol; 1997 Nov 25; 37(1):23-7. PubMed ID: 9018028
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.
    Ahlskog JE, Muenter MD, McManis PG, Bell GN, Bailey PA.
    Mayo Clin Proc; 1988 Sep 25; 63(9):876-86. PubMed ID: 3045435
    [Abstract] [Full Text] [Related]

  • 20. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
    Cedarbaum JM, Kutt H, McDowell FH.
    Neurology; 1989 Nov 25; 39(11 Suppl 2):38-44; discussion 59. PubMed ID: 2586762
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.